Illustration: Sarah Grillo/Axios
InTandem Capital Partners is prepping Vivo Infusion to come to market later this year, six sources familiar with the process tell Axios.
Why it matters: The auction will gauge how much sponsors are willing to pay for larger-scale, PE-backed infusion investments.
